[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP

Molecular Pharmacology

Volumn 63, Issue 6, 2003, Pages 1364-1372

  Corbin, Jackie D ^a   Blount, Mitsi A ^a   Weeks II, James L ^a   Beasley, Alfreda ^a   Kuhn, Karl P ^a   Ho, Yew S J ^b   Saidi, Layla F ^b   Hurley, James H ^b   Kotera, Jun ^a   Francis, Sharron H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYLPYRIDIN 4 YL)METHYL 4 (3,4,5 TRIMETHOXYPHENYL) 8 (PYRIMIDIN 2 YL)METHOXY 1,2 DIHYDRO 1 OXO 2,7 NAPHTHYRIDINE 3 CARBOXYLIC ACID METHYL ESTER; CYCLIC GMP; GUANOSINE PHOSPHATE; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL; T 0156; UNCLASSIFIED DRUG; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PIPERAZINE DERIVATIVE; TRITIUM;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SUBSTRATE COMPLEX; ISOTOPE LABELING; MOLECULAR DYNAMICS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BINDING SITE; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; GENETIC TRANSFECTION; HUMAN; INSECT; LUNG; MALE; METABOLISM; RADIOASSAY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BINDING SITES; CELLS, CULTURED; CYCLIC GMP; DRUG INTERACTIONS; HUMANS; INSECTS; LUNG; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RADIOLIGAND ASSAY; TRANSFECTION; TRITIUM;

EID: 0038024614     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.6.1364     Document Type: Article

References (44)

1. Aravind L and Ponting CP (1997) The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458-459.
2. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, and Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171.
3. Beavo JA, Hardman JG, and Sutherland EW (1971) Stimulat]on of adenosine 3′,5′monophosphate hydrolysis by guanosine 3′,5′-monophosphate. J Biol Chem 246: 3841-3846.
4. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Charbonneau H (1990) Structure-function relationships among cyclic nucleotide phosphodiesterases, in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action (Beavo J and Houslay MD eds) pp 267-296, Wiley, New York.
7. Charbonneau H, Prusti RK, LeTrong H, Sonnenburg WK, Mullaney PJ, Walsh KA, and Beavo JA (1990) Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. Proc Natl Acad Sci USA 87:288-292.
8. Conti M (2000) Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol 14:1317-1327.
9. Corbin JD and Francis SH (1999) Cyclic GMP Phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732.
10. Corbin JD, Gettys TW, Blackmore PF, Beebe SJ, Francis SH, Glass DB, Redmon JB, Sheorain VS, and Landiss LR (1988) Purification and assay of cAMP, cGMP and cyclic nucleotide analogs in cells treated with cyclic nucleotide analogs. Methods Enzymol 159:74-82.
11. Corbin JD, Turko IV, Beasley A, and Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767.
12. Degerman E, Belfrage P, and Manganiello VC (1997) Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826.
13. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, and Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphediesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707.
14. Flockhart DA and Corbin JD (1984) Preparation of the catalytic subunit of cAMPdependent protein kinase, in Brain Receptor Methodologies (Marangos PJ, Campbell IC and Cohen RM eds) pp 209-215, Academic Press, Inc., Orlando.
15. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, and Corbin JD (2002) Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem 277:47581-47587.
16. Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, and Corbin JD (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14:81-92.
17. Francis SH, Colbran JL, McAllister-Lucas LM, and Corbin JD (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem 269:22477-22480.
18. Francis SH and Corbin JD (1988) Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol 159:722-729.
19. Francis SH, Thomas MK, and Corbin JD (1990) Cyclic GMP-binding cyclic GMPspecific phosphodiesterase from lung, in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action (Beavo J and Houslay MD eds) pp 117-140, Wiley, New York.
20. Francis SH, Turko IV, and Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
21. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, and Omori K (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445.
22. Gopal VK, Francis SH, and Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304-3312.
23. Jiang H, Colbran JL, Francis SH, and Corbin JD (1992) Direct evidence for crossactivation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 267:1015-1019.
24. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, and Huang Z (2001a) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40:10179-86.
25. Liu L, Underwood T, Li H, Pamukcu R, and Thompson WJ (2001b) Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP-specific phosphodiesterase. Cell Signal 13:1-7.
26. Martins TJ, Mumby MC, and Beavo JA (1982) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 257:1973-1979.
27. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, LeTrong H, Colbran JL, Thomas MK, Walsh KA, Francis SH, et al. (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 268:22863-22873.
28. Mochida H, Takagi M, Inoue H, Noto T, Yano K, Fujishige K, Sasaki T, Yuasa K, Kotera J, Omori K, et al. (2002) Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharacol 456:91-98.
29. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, and Friebe A (2001) Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155:271-278.
30. Murthy KS (2001) Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 360:199-208.
31. Okada D and Asakawa S (2002) Allosteric activation of cGMP-specific, cGMPbinding phosphodiesterase (PDE5) by cGMP. Biochemistry 41:9672-9679.
32. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, and Beavo JA (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277:3310-3317.
33. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, et al. (2001) The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13:282-290.
34. Schneider HH, Schmiechen R, Brezinski M, and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
35. Soderling SH, Bayuga SJ, and Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071-7076.
36. Stroop SD and Beavo JA (1991) Structure and function studies of the cGMPstimulated phosphodiesterase. J Biol Chem 266:23802-23809.
37. Thomas MK, Francis SH, and Corbin JD (1990a) Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 265:14964-14970.
38. Thomas MK, Francis SH, and Corbin JD (1990b) Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265:14971-14978.
39. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, and Livi GP (1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804.
40. Turko IV, Ballard SA, Francis SH, and Corbin JD (1999) Inhibition of cyclic GMPbinding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56:124-130.
41. Turko IV, Haik TL, McAllister-Lucas LM, Burns F, Francis SH, and Corbin JD (1996) Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J Biol Chem 271:22240-22244.
42. Weber G (1975) Energetics of ligand binding to protein. Adv Protein Chem 29:1-83.
43. Wyatt TA, Naftilan AJ, Francis SH, and Corbin JD (1998) ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274:H448-H455.
44. Yamazaki A, Sen I, Bitensky MW, Casnellie JE, and Greengard P (1980) Cyclic GMP-specific, high affinity, noncatalytic binding sites on light-activated phosphodiesterase. J Biol Chem 255:11619-11624.